Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.

Regardless of t(11;14), combination of venetoclax with S63845 is a promising strategy in enhancing venetoclax sensitivity or overcoming venetoclax resistance in myeloma therapy, hence warrant future clinical studies.